ArticleGeburtshilfe und Frauenheilkunde2016

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.

L Schröder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.